577 related articles for article (PubMed ID: 25776529)
21. Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling.
Shigesawa T; Maehara O; Suda G; Natsuizaka M; Kimura M; Shimazaki T; Yamamoto K; Yamada R; Kitagataya T; Nakamura A; Suzuki K; Ohara M; Kawagishi N; Umemura M; Nakai M; Sho T; Morikawa K; Ogawa K; Ohnishi S; Sugiyama M; Mizokami M; Takeda H; Sakamoto N
Carcinogenesis; 2021 Feb; 42(1):58-69. PubMed ID: 32449510
[TBL] [Abstract][Full Text] [Related]
22. Interrupting the FGF19-FGFR4 Axis to Therapeutically Disrupt Cancer Progression.
Lang L; Shull AY; Teng Y
Curr Cancer Drug Targets; 2019; 19(1):17-25. PubMed ID: 29557750
[TBL] [Abstract][Full Text] [Related]
23. Up-regulation of FGF15/19 signaling promotes hepatocellular carcinoma in the background of fatty liver.
Cui G; Martin RC; Jin H; Liu X; Pandit H; Zhao H; Cai L; Zhang P; Li W; Li Y
J Exp Clin Cancer Res; 2018 Jul; 37(1):136. PubMed ID: 29973237
[TBL] [Abstract][Full Text] [Related]
24. FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3β/β- catenin signaling cascade via FGFR4 activation.
Zhao H; Lv F; Liang G; Huang X; Wu G; Zhang W; Yu L; Shi L; Teng Y
Oncotarget; 2016 Mar; 7(12):13575-86. PubMed ID: 26498355
[TBL] [Abstract][Full Text] [Related]
25. FGF401 and vinorelbine synergistically mediate antitumor activity and vascular normalization in FGF19-dependent hepatocellular carcinoma.
Huynh H; Prawira A; Le TBU; Vu TC; Hao HX; Huang A; Wang Y; Porta DG
Exp Mol Med; 2020 Nov; 52(11):1857-1868. PubMed ID: 33235319
[TBL] [Abstract][Full Text] [Related]
26. Up-regulation of fibroblast growth factor 19 and its receptor associates with progression from fatty liver to hepatocellular carcinoma.
Li Y; Zhang W; Doughtie A; Cui G; Li X; Pandit H; Yang Y; Li S; Martin R
Oncotarget; 2016 Aug; 7(32):52329-52339. PubMed ID: 27447573
[TBL] [Abstract][Full Text] [Related]
27. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib.
Gao L; Wang X; Tang Y; Huang S; Hu CA; Teng Y
J Exp Clin Cancer Res; 2017 Jan; 36(1):8. PubMed ID: 28069043
[TBL] [Abstract][Full Text] [Related]
28. Discovery of novel FGFR4 inhibitors through a build-up fragment strategy.
Kim J; Im CG; Oh K; Lee JM; Al-Rubaye F; Min KH
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2343350. PubMed ID: 38655602
[TBL] [Abstract][Full Text] [Related]
29. Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma.
Lin ZZ; Hsu C; Jeng YM; Hu FC; Pan HW; Wu YM; Hsu HC; Hu MC; Cheng AL
Liver Int; 2019 Sep; 39(9):1682-1691. PubMed ID: 30698907
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling.
Pai R; Dunlap D; Qing J; Mohtashemi I; Hotzel K; French DM
Cancer Res; 2008 Jul; 68(13):5086-95. PubMed ID: 18593907
[TBL] [Abstract][Full Text] [Related]
31. Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19.
Zhou M; Wang X; Phung V; Lindhout DA; Mondal K; Hsu JY; Yang H; Humphrey M; Ding X; Arora T; Learned RM; DePaoli AM; Tian H; Ling L
Cancer Res; 2014 Jun; 74(12):3306-16. PubMed ID: 24728076
[TBL] [Abstract][Full Text] [Related]
32. Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma.
Poh W; Wong W; Ong H; Aung MO; Lim SG; Chua BT; Ho HK
Mol Cancer; 2012 Mar; 11():14. PubMed ID: 22439738
[TBL] [Abstract][Full Text] [Related]
33. FGF19 Protects Hepatocellular Carcinoma Cells against Endoplasmic Reticulum Stress via Activation of FGFR4-GSK3β-Nrf2 Signaling.
Teng Y; Zhao H; Gao L; Zhang W; Shull AY; Shay C
Cancer Res; 2017 Nov; 77(22):6215-6225. PubMed ID: 28951455
[TBL] [Abstract][Full Text] [Related]
34. First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma.
Kim RD; Sarker D; Meyer T; Yau T; Macarulla T; Park JW; Choo SP; Hollebecque A; Sung MW; Lim HY; Mazzaferro V; Trojan J; Zhu AX; Yoon JH; Sharma S; Lin ZZ; Chan SL; Faivre S; Feun LG; Yen CJ; Dufour JF; Palmer DH; Llovet JM; Manoogian M; Tugnait M; Stransky N; Hagel M; Kohl NE; Lengauer C; Sherwin CA; Schmidt-Kittler O; Hoeflich KP; Shi H; Wolf BB; Kang YK
Cancer Discov; 2019 Dec; 9(12):1696-1707. PubMed ID: 31575541
[TBL] [Abstract][Full Text] [Related]
35. Combination of FGFR4 inhibitor Blu9931 and 5-fluorouracil effects on the biological characteristics of colorectal cancer cells.
Jiang D; Li J; Li J; Wang M; Han C; Wang X; Zhao C; Ye Y
Int J Oncol; 2017 Nov; 51(5):1611-1620. PubMed ID: 29048661
[TBL] [Abstract][Full Text] [Related]
36. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models.
Desnoyers LR; Pai R; Ferrando RE; Hötzel K; Le T; Ross J; Carano R; D'Souza A; Qing J; Mohtashemi I; Ashkenazi A; French DM
Oncogene; 2008 Jan; 27(1):85-97. PubMed ID: 17599042
[TBL] [Abstract][Full Text] [Related]
37. FGFR4 provides the conduit to facilitate FGF19 signaling in breast cancer progression.
Zhao X; Xu F; Dominguez NP; Xiong Y; Xiong Z; Peng H; Shay C; Teng Y
Mol Carcinog; 2018 Nov; 57(11):1616-1625. PubMed ID: 30074276
[TBL] [Abstract][Full Text] [Related]
38. Fibroblast Growth Factor 15/19 in Hepatocarcinogenesis.
Alvarez-Sola G; Uriarte I; Latasa MU; Urtasun R; Bárcena-Varela M; Elizalde M; Jiménez M; Rodriguez-Ortigosa CM; Corrales FJ; Fernández-Barrena MG; Berasain C; Avila MA
Dig Dis; 2017; 35(3):158-165. PubMed ID: 28249259
[TBL] [Abstract][Full Text] [Related]
39. Molecular subclasses of hepatocellular carcinoma predict sensitivity to fibroblast growth factor receptor inhibition.
Schmidt B; Wei L; DePeralta DK; Hoshida Y; Tan PS; Sun X; Sventek JP; Lanuti M; Tanabe KK; Fuchs BC
Int J Cancer; 2016 Mar; 138(6):1494-505. PubMed ID: 26481559
[TBL] [Abstract][Full Text] [Related]
40. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma.
Miura S; Mitsuhashi N; Shimizu H; Kimura F; Yoshidome H; Otsuka M; Kato A; Shida T; Okamura D; Miyazaki M
BMC Cancer; 2012 Feb; 12():56. PubMed ID: 22309595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]